US Stock MarketDetailed Quotes

Allogene Therapeutics (ALLO)

Watchlist
  • 2.150
  • +0.020+0.94%
Close May 1 16:00 ET
  • 2.148
  • -0.002-0.11%
Post 20:01 ET
712.25MMarket Cap-2.47P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Allogene Therapeutics (ALLO) Revenue Breakdown Overview

By Business/Source

Currency:USD
2024/FY
Stock NameRevenueRatio
Developing and commercializing genetically engineered allogeneic T cell product candidates for the22K100.00%

By Country/Region

Currency:USD
2024/FY
Stock NameRevenueRatio
United States22K100.00%
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +17.90%
Sample Name
Sample Code
 +13.59%
Sample Name
Sample Code
 +12.81%
4
VanEck Oil Services ETF
OIH
+11.45%
5
United Sts 12 Month Oil Fd Lp Unit Ben Int
USL
+9.96%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +11.87%
Sample Name
Sample Code
 +6.69%
Sample Name
Sample Code
 +6.27%
4
KE Holdings
BEKE
+5.44%
5
New Oriental
EDU
+4.10%
View More
Middle East conflict spreads to the stock market! How should investors respond?
On May 1, the more than two-month-long military conflict involving the US, Israel, and Iran will reach a legal milestone, potentially increa Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -